Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06364267

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

Randomized Double Blind Phase II Trial of Baby Exemestane vs Baby Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
140 (estimated)
Sponsor
Andrea DeCensi · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.

Detailed description

This is a multicenter, randomized, double blind phase II trial. Eligible patients will be randomized in a 1:1 ratio to: ARM 1: BabyEXE Arm, 25 mg eod, typically every odd day of the monthly calendar for 12 monthsor unless progression, SAE, medical decision, patient withdrawal occur. ARM 2: BabyTAM Arm, 10 mg eod, typically every odd day of the monthly calendar for 12 months or unless progression, SAE, medical decision, patient withdrawal occur. Blinding will be guaranteed by over-encapsulation of active tablet agents with an AA capsule in a 6-month bottle. In both arms, treatment should begin within 30 days from randomization. Exemstane and Tamoxifen will be provided for free by the Study Sponsor. After study completion, participants will be unblinded and treated according to local guidelines. Clinical visit will be performed every 6 months (±14 days) with physical examination vital signs and weight and girth measurement, ECOG PS, MENQOL questionnaire (0, 6, 12 months), review of self-reported compliance, concomitant medications, AEs assessment, and physical exam. Telephone/video contact may be allowed at 3 and 9 months, whereas baseline, 6 months and 12 months visits are necessary for blood collection and biomarker assessment. Blood serum for centralized storage at IEO, Milan, Italy, will be collected at different time points.

Conditions

Interventions

TypeNameDescription
DRUGTamoxifen 10 MGBlinded tamoxifen 10 mg every other day
DRUGExemestane 25 MGBlinded exemestane 25 mg every other day

Timeline

Start date
2025-10-01
Primary completion
2027-01-31
Completion
2027-01-31
First posted
2024-04-15
Last updated
2025-11-18

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06364267. Inclusion in this directory is not an endorsement.